

DAFTAR PUSTAKA

- Ahuja, S. & Rasmussen, H., 2007. *HPLC METHOD DEVELOPMENT*. first ed. Amsterdam, Netherlands: ELSEVIER.
- Ali, M., Salam, M., Asad, M. & Saifuzzaman, M., 2009. Study on Release Pattern and Potency Status of Ketoprofen Solid Dosage Forms Available in the Pharma-Market of Bangladesh., 4:. *Journal of Pharmacology and Toxicology*, pp. 205-212.
- Amidon, G., Lennernas, H., Shah, V. & Crison, J., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.s. 12, 413–420.. *Pharm. Re*, Volume 12, pp. 413-420.
- Anand, O., Yu, L. X., Conner, D. P. & Davit, B. M., 2011. Dissolution Testing for Generic Drugs: An FDA Perspective. *AAPS J.*, 13(3), pp. 328-335.
- Ansari M, K. M. T. J., 2004. The development and validation of a dissolution method for clomipramine solid dosage forms.. *Dissol Technol.*, Volume 11, pp. 16-24.
- Ansel, H., 1989. *Introduction to Pharmaceutical Dosage Form*. 4 ed. Philadelphia: Lea&Febiger.
- Arida, A. I., & Al-Tabakha, M. M. (2007). Encapsulation of ketoprofen for controlled drug release. *European journal of pharmaceutics and biopharmaceutics*, 66(1), 48-54.
- Ashokraj, Y. et al., 2016. Discriminatory dissolution method development and validation of etoricoxib tablets.. *Dissolut Technol*, 23(2), pp. 30-34..
- Bajaj, S., Singla, D., & Sakhuja, N. (2012). Stability testing of pharmaceutical products. *Journal of applied pharmaceutical science*, 2(3), 129-138.
- Bempong, D. K. & Bhattacharyya, L., 2005. Development and validation of a stability-indicating high-performa liquid chromatographic assay for ketoprofen topical penetrating gel. . *Journal of Chromatography A*, 1073(1-2), pp. 341-346.
- Blanco, M., Gonzalez, J., Torras, E. & Valverde, I., 2003. Enantiomeric purity determination of ketoprofen by capillary electrophoresis: development and validation of the method,. *Anal Bioanal Chem*, Volume 375, p. 157–163.
- BP, 2017. *British Pharmacopoeia (B.P.)*. London, UK.: The Stationery Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA).
- BPOM RI, 2020. <https://cekbpom.pom.go.id/>. [Online] Available at: <http://cekbpom.pom.go.id/index.php/home/produk> [Accessed 22 juni 2020].

- Breier, A. R., Paim, C. S., Steppe, M. & Schapoval, E. E., 2005. Development and Validation of Dissolution Tests for Fexofenadine Hydrochloride Capsules and Coated Tablets. *J Pharm Pharmaceut Sci*, 8(289-298).
- Brown, C. K., 2005. *Dissolution method development: an industry perspective*, *Pharmaceutical Dissolution Testing*, 1st ed. New York pp: Taylor & Francis.
- Cerciello, A. et al., 2016. Natural polysaccharides platforms for oral controlled release of ketoprofen lysine salt. *Drug development and industrial pharmacy*, 42(12), pp. 2063-2069..
- Cheng, B. et al., 2018. Two kinds of ketoprofen enteric gel beads (CA and CS-SA) using biopolymer alginate. *Asian journal of pharmaceutical sciences*, 13(2), pp. 120-130.
- Corrigan, O. I., Devlin, Y. & Butler, J., 2003. Influence of dissolution medium buffer composition on ketoprofen. *International Journal of Pharmaceutics*, Volume 254, p. 147–154.
- Costa, P. & Lobo, J. M. S., 2001. Modeling and comparison of dissolution profiles.. *European journal of pharmaceutical sciences*, 13(2), pp. 123-133..
- Craig, D., 1993. , 1993. The use of self-emulsifying systems as a means of improving drug delivery.. *In: Bulletin Technique Gattefosse*, pp. 21-31.
- D'Arcy, D. M., Corrigan, O. I. & Healy, A. M., 2006. Evaluation of hydrodynamics in the basket dissolution apparatus using computational fluid dynamics—dissolution rate implications. *European journal of pharmaceutical sciences*, 27(2-3), pp. 259-267.
- Das, U., Biswas, G. R. & Majee, S. B., 2014. Discriminating power of dissolution medium in comparative study of solid dispersion tablets of Biopharmaceutics Classification System class 2 drug.. *African Journal of Pharmacy and Pharmacology*, 8(15), pp. 408-412.
- Dokoumetzidis, A. & Macheras, P., 2006. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. *International journal of pharmaceutics*, 321(1-2), pp. 1-11.
- Dressman, J. B., Gordon, L. A., Christos, R. & Vinod, P. S., 1998. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms.. *Pharmaceutical Research*, Volume 15, pp. 11-22.
- DrugBank, 2020. *Drug Bank database*. [Online]
Available at: <https://www.drugbank.ca/drugs/DB01009>
[Accessed 15 June 2020].
- Dvořák, J. et al., 2004. Simultaneous HPLC determination of ketoprofen and its degradation products in the presence of preservatives in pharmaceuticals.. *Journal of pharmaceutical and biomedical analysis*, 36(3), pp. 625-629.

- FDA, 1997. *SUPAC-MR : Modified Release Solid Oral Dosage Forms. Scale-Up and Post Approval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation*. Washington,DC, U.S. Government Printing Office.
- Fossgreen, J., 1976. Ketoprofen: A survey of current publications. *Scand J. Rheumatol.*, 5(suppl 14), pp. 7-32.
- Friedel, H. . D. et al., 2018. FIP Guidelines for Dissolution Testing of Solid Oral Products. *Journal of Pharmaceutical Sciences*, Volume xxx, pp. 1-8.
- Fudholi, A., 2013. *Disolusi & Pelepasan obat in vitro*. 1 ed. Yogyakarta: Pustaka Pelajar.
- Ghube, K., Khade, P. & Bhosale, A., 2020. A Review on Enteric Coating. *Journal of Current Pharma Research*, 10(4), pp. 3848-3862..
- ICH, 2018. *ICH Harmonised Guideline, Biopharmaceutics Classification System-Based*. s.l.:s.n.
- ICH, I., 2005. *Q2 (R1): Validation of analytical procedures: text and methodology, In International Conference on Harmonization*. Geneva, s.n.
- Jamali, F. & Brocks, D., 1990. Clinical pharmacokinetics of ketoprofen and its enantiomers. *Clin Pharmacokinet*, 19(3), p. 197–217.
- Jan, S. U. et al., 2012. Release pattern of three new polymers in Ketoprofen controlled-release tablets. *African Journal of Pharmacy and Pharmacology*, 6(9), pp. 601-607.
- Kantor, T. G., 1986. Ketoprofen: a review of its pharmacologic and clinical properties. *Pharmacotherapy. The Journal of Human Pharmacology and Drug Therapy*, 6(3), pp. 93-102.
- Karkossa, F., & Klein, S. (2017). Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets. *Journal of Pharmacy and Pharmacology*, 69(10), 1327-1340.
- Kormosh, Z., Hunka, I., Basel, Y.; Spectrophotometric determination of ketoprofen and its application in pharmaceutical analysis; *Acta Poloniae Pharmaceutica*, (2009); 66: 3–9.
- Kumar, M. et al., 2018. Dissolution Method Development and Validation for Tablet Dosage form of Telmisartan Using UV Spectrophotometric Method.. *Journal of Chemical and Pharmaceutical Research*, 10(5), pp. 148-156.
- Lei, L. U. O., Tan, M. & Yonghuang, L. U. O., 2019. Determination of related substances in ketoprofen injection by RP-HPLC method.. *Pakistan journal of pharmaceutical sciences*, 32(4).
- Leuner, C. & Dressman, J., 2000. Improving drug solubility for oral delivery using solid dispersions. *Eur. J. Pharm. Biopharm*, Volume 50, pp. 47-60.
- Liversidge, G. G., 1981. Ketoprofen , Analytical Profile of Drug Substances. Volume 10, pp. 443-471.

- Long, M. & Chen, Y., 2009. Dissolution testing of solid products. In: *Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice*. s.l.:Academic Press., pp. 319-340.
- Maderuelo, C., Lanao, J. M. & Z. A., 2019. Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability. *European Journal of Pharmaceutical Sciences*, 138(105019), pp. 1-5.
- Martindale, 2009. *Martindale : The Complete Drug Reference*. 36th ed. London: The Pharmaceutical Press.
- Matsui H, et al., 2011. The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine.. *J Clin Biochem Nutr*, 48(2), p. 07–111.
- Medeiros, S. F. et al., 2017. Synthesis and characterization of poly (N-vinylcaprolactam)-based spray-dried microparticles exhibiting temperature and pH-sensitive properties for controlled release of Ketoprofen. *Drug development and industrial pharmacy*, 43(9), pp. 1519-1529.
- Mendez, A. S. S. M. & S. E. E., 2003. Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. *Journal of pharmaceutical and biomedical analysis*, 33(5), pp. 947-954.
- Menkes, R., 2014. *Farmakope Indonesia*. V ed. Jakarta: Departemen Kesehatan RI.
- Moore, J. W. & Flanner, H. H., 1996. (1996). Mathematical comparison of dissolution profiles. *Pharmaceutical technology*, 20(6), pp. 64-74..
- Parmar, A. & Sharma, S., 2016. Derivative UV-vis absorption spectra as an invigorated spectrophotometric method for spectral resolution and quantitative analysis: Theoretical aspects and analytical applications: A review.. *TrAC Trends in Analytical Chemistry*, Volume 77, pp. 44-53.
- Peters, F. T. & Maurer, H. . H., 2004. Bioanalytical method validation. pharmaceutical methods. *AAPS PharmSciTech*, 5(1), pp. 106-118..
- Pillay. V & Fassihi, R., 1998. Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. *J. Controlled Release*. 55(3), pp. 45-55.
- Qureshi, S. A., Caillé, G., L. Y. & McGilveray, I. J., 1994. Pharmacokinetics of two enteric-coated ketoprofen products in humans with or without coadministration of omeprazole and comparison with dissolution findings. *Pharmaceutical research*, 11(11), pp. 1669-1672.
- Rathore, V. S., Tanwar, Y. S., Rathore, G. S., & Ahmed, J. A. (2014). A Review on Enteric Coating Technology. *International Journal of Chemistry and Pharmaceutical Sciences*, 2(9), 1155–1159.
- Rençber, S., Karavana, S. Y. & Özyazici, M., 2009. Bioavailability file: ketoprofen. *FABAD Journal of Pharmaceutical Sciences*, 34(4), p. 203.

- RI, B., 2020. *PioNas.pom.go.id*. [Online]
Available at: <http://pionas.pom.go.id/monografi/ketoprofen>
[Accessed 6 June 2020].
- Shah, V., T. Y., S. P. & Liu, J.-P., 1998. In vitro dissolution profile comparison—statistics and analysis of the similarity factor f_2 . *Pharmaceutical Research*, 15(6), p. 889 – 896 ..
- Sheng, J., Kasim, N., Chandrasekharan, R. & Amidon, G., 2006. Solubilization and Dissolution of Insoluble Weak Acid, Ketoprofen: Effect of pH Combined Surfactant. *Eur J Pharm Sci*, Volume 29, pp. 306-314.
- SHOHIN, I. E. et al., 2012. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms : Ketoprofen 101(10), .. *Journal of Pharmaceutical Sciences*, 101(10), p. 3593–3603.
- Tiwari, G. et al., 2010. Primary and novel approaches for colon targeted drug delivery-A review.. *International Journal of Drug Delivery*, 2(1).
- Tsuru, S., Maki, M., Yamasoto, S. & Terahara, 2017. *Ketoprofen-containing poultice*. Washington, DC.US, Patent No. 9,707,194.
- USP, 2016. *The United States Pharmacopeia : the National Formulary (USP39-NF34)*. Easton: Mack Publishing Co..
- Vaghela, B. et al., 2011. Development and validation of dissolution procedures. *Journal of applied pharmaceutical science*, 1(03), pp. 50-56.
- Veys, E. M., 1991. 20 Years' Experience with Ketoprofen. *Scandinavian Journal of Rheumatology*, 19(sup90), pp. 3-44.
- Vyas, P. S. & Khar, K. R., 2002. *Controlled drug delivery: Concepts and advances*. 1 ed. New Delhi: Vallabh Prakashan.
- Wang, Q., Ma, D. & Higgins, J. P., 2006. Analytical method selection for drug product dissolution testing.. *Dissolution Technologies*, 13(3), p. 6.
- Wei, Q., Yang, F. & Luan, L., 2013. Preparation and in vitro/in vivo evaluation of a ketoprofen orally disintegrating/sustained release tablet. *Drug development and industrial pharmacy*, 39(6), pp. 928-934.
- Williams RL, U. R., 1988. The clinical pharmacology of ketoprofen. *J Clin Pharmacol*, Volume 28, pp. 13-22..
- Wong, C. Y., Yeh, M. K. & Wang, D. P., 1992. High-performance liquid chromatographic determination of ketoprofen in pharmaceutical dosage forms and plasma.. *Journal of Liquid Chromatography & Related Technologies*, 15(8), pp. 1215-1225.
- Yadav, K. N. et al., 2016. QbD-based development and validation of a stability-indicating HPLC method for estimating ketoprofen in bulk drug and proniosomal vesicular system. *Journal of Chromatographic Science*, 54(3), pp. 377-389.

Yazdanian, M., K, B., J. C. & A., H., 2004. The “high solubility” definition of the current FDA guidance on biopharmaceutical drugs. *Pharm Res*, Volume 21, p. 293–299.

Zafar, F. et al., 2017. KETOPROFEN. *The Professional Medical Journal*, Volume 01, pp. 10-13.

Zafar, F. et al., 2017. Pharmaceutical and in vitro therapeutic equivalence studies of ketoprofen enteric coated 100 mg tablets. s, 30(1).. *Pakistan journal of pharmaceutical sciences*, 30(1), pp. 179-186.

Zhao, H., Cafiero, S., Williams, Z. & Bynum, K. C., 2011. Practical considerations for the development of a robust two-step dissolution test for enteric-coated immediate-and extended-release solid oral dosage formulations.. *Dissolution Technol.*, 18(1), pp. 6-10.

Zheng, X., Zhou, Y. & Liu, P., 2017. Content Determination of Ketoprofen in Ketoprofen Enteric-coated Capsules by Improving HPLC.. *China Pharmacy*., 28(18), pp. 2579-2581.



